Use of high-resolution volumetric MR spectroscopic imaging in assessing treatment response of glioblastoma to an HDAC inhibitor.
OBJECTIVE
Improved predictive imaging would enable personalization and adjustment of treatment, which are critical for patients with glioblastomain whom therapy is likely to fail. This article describes the use of MR spectroscopic imaging (MRSI) to predict early clinical and behavioral response to a therapy and an effort to develop high-resolution, volumetric MRSI to improve its clinical application.


CONCLUSION
MRSI may enable quantitative analysis of brain tumor response, offering a precise tool for monitoring of patients in clinical trials.
['Shim|Hyunsuk|H|', 'Wei|Li|L|', 'Holder|Chad A|CA|', 'Guo|Ying|Y|', 'Hu|Xiaoping P|XP|', 'Miller|Andrew H|AH|', 'Olson|Jeffrey J|JJ|']
D001923:Brain Chemistry D001932:Brain Neoplasms D005909:Glioblastoma D056572:Histone Deacetylase Inhibitors D006801:Humans D009682:Magnetic Resonance Spectroscopy
MR spectroscopic imaging glioblastoma epigenetic modification histone deacetylase (HDAC) vorinostat